scholarly journals Use of antithrombin III in cancer patients with sepsis complicated with disseminated intravascular coagulopathy

Critical Care ◽  
10.1186/cc154 ◽  
1998 ◽  
Vol 2 (Suppl 1) ◽  
pp. P024
Author(s):  
M Polansky ◽  
J Varon ◽  
WK Hoots
Keyword(s):  
Cancer Patients ◽  
Antithrombin Iii ◽  
Disseminated Intravascular Coagulopathy ◽  
Intravascular Coagulopathy

Two automated methods for plasma antithrombin III compared, and the clinical significance of the results.

1982 ◽  
Vol 28 (11) ◽  
pp. 2249-2253 ◽  
Author(s):  
W Prellwitz ◽  
K F Schmitt ◽  
M Machner ◽  
C J Schuster ◽  
L Weilemann
Keyword(s):  
Antithrombin Iii ◽  
Heparin Therapy ◽  
Disseminated Intravascular Coagulopathy ◽  
Continuous Therapy ◽  
Men And Women ◽  
Short Intervals ◽  
At Iii ◽  
Intravascular Coagulopathy ◽  
Abdominal Operations ◽  
Automated Methods

Abstract Antithrombin III (AT III) activity was determined with two different new chromogenic substances--Chromozym-TH (Tos-Gly-Arg-p-nitroanilide; Boehringer Mannheim) and alpha-N-carbobenzyl-oxy-L-lysine-thiobenzyl ester (Du Pont)--with both a discrete (aca) and a centrifugal analyzer (COBAS BIO). The correlation between the Chromozym-TH/centrifugal analyzer and Du Pont ester/aca methods was good (r = 0.9890). Precision within and between runs was similar to that for typical enzymic determinations. AT III in plasma of 226 healthy men and women ranged from 76.6 to 141.1% (100% = "normal"). We found no significant differences ascribable to oral contraceptives. AT III activity was decreased in 27% of patients with acute thromboembolic diseases (n = 62), in 48% of patients the first day after abdominal operations without complications (n = 78), and in 100% of patients with reversible or irreversible shock (n = 58). In patients receiving continuous therapy with heparin (1500 USP units/h) we saw no decrease in AT III within 96 h of beginning treatment. Plasma from 14 of 16 patients with disseminated intravascular coagulopathy showed a decrease in AT III of from 17 to 51% of normal before and during heparin therapy. We then treated all 16 patients with AT III concentrate. During such treatment, AT III in plasma must be monitored over short intervals to assure that sufficiently high proportions of AT III (greater than 70% of normal) are reached.

Disseminated Intravascular Coagulopathy in Critically Ill Patients in Amman, Jordan

2021 ◽  
pp. 109980042110172
Author(s):  
Eman Mahmoud Qasim Emleek ◽  
Amani Anwar Khalil
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Scoring System ◽  
Elevated Serum ◽  
Underlying Disease ◽  
Disseminated Intravascular Coagulopathy ◽  
Period Prevalence ◽  
Lower Baseline ◽  
Intravascular Coagulopathy

Background: The disseminated intravascular coagulation (DIC) is under-recognized in critically ill patients. The International Society of Thrombosis and Haemostasis (ISTH; DIC) provides a useful scoring system for accurate DIC identification. The study investigated the period prevalence of ISTH DIC from 2015 to 2017 in critically ill patients. Methods: In this multi-center, retrospective observational study, we included all patients identified with a DIC code or medically diagnosed with DIC during all admissions. Based on ISTH DIC scores ≥ 5, patients were classified with overt DIC. Results: A total of 220 patients were included in this study. The period prevalence of DIC was 4.45%. The point prevalence of DIC has increased from 3.49% to 5.58% from 2015 to 2017 (27.7% female; median age 61.6 years). Based on the ISTH-Overt DIC criteria, 45.2% of the sample had sepsis. Overt DIC patients had significantly lower baseline hemoglobin (HB; t = 2.137, df = 193, p = 0.034), platelet count ( t = 3.591, df = 193, p < 0.001) and elevated serum creatinine level ( M = 2.1, SD = 1.5, t = 2.203, df = 193, p = 0.029) compared to non–Overt DIC. There was a statistically significant elevation in FDPs among Overt DIC compared to non–Overt DIC (χ2 = 30.381, df = 1, p < 0.001). Overt DIC patients had significantly prolonged PT ( U = 2,298, z = 5.7, p < 0.001), PTT ( U = 2,334, z = 2.0, p = 0.045) and INR ( U = 2,541, z = 5.1, p < 0.001) compared to those with non–Overt DIC. Conclusion: The ISTH overt-DIC score can be used in critically ill patients regardless of the underlying disease. Efforts are required to predict and identify overt DIC using a valid scoring system on admission and follow-up of adult patients admitted to ICU.

Evaluation of obstetrical patients with disseminated intravascular coagulopathy – tertiary center experience

2015 ◽  
Vol 29 (18) ◽  
pp. 2929-2933 ◽  
Author(s):  
Serdar Başaranoğlu ◽  
Mehmet Sıddık Evsen ◽  
Elif Ağaçayak ◽  
Senem Yaman Tunç ◽  
Zülfikar Yılmaz ◽  
...  
Keyword(s):  
Disseminated Intravascular Coagulopathy ◽  
Tertiary Center ◽  
Intravascular Coagulopathy

scholarly journals Emergency Cardiac Surgery in Patients on Oral Anticoagulants

2021 ◽  
Author(s):  
Rami Akhrass ◽  
A. Marc Gillinov ◽  
Faisal Bakaeen ◽  
Scott Cameron ◽  
Jay Bishop ◽  
...  
Keyword(s):  
Circulatory Arrest ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Difficult Patient ◽  
Disseminated Intravascular Coagulopathy ◽  
Reversal Agents ◽  
Coagulation Profile ◽  
Intravascular Coagulopathy ◽  
Time To Onset ◽  
Case Basis

Emergency surgery, blood transfusion, and reoperation for bleeding have been associated with increased morbidity and mortality. Every effort is made to optimize patients preoperatively including cessation of oral anticoagulants in an attempt to normalize the coagulation profile. The recent explosive use of direct oral anticoagulants (DOACs) and antiplatelet medications has made the above more difficult. Cardiopulmonary bypass (CPB), with its associated fibrinolysis and platelet consumption, may exacerbate a pre-existing coagulopathy. In addition, the underlying surgical pathology, such as endocarditis accompanied by sepsis and disseminated intravascular coagulopathy (DIC) or aortic dissection requiring hypothermia and circulatory arrest, can aggravate an already challenged hematological profile. Ensuring a dry operative field upon entry by correcting the coagulopathy is offset by the concern of potentially hindering efforts to anticoagulate the patient in preparation for CPB, in addition to possibly creating a hypercoagulable state that could increase the risk of thromboembolic events. Management is challenging and decisions are typically made on a case-by-case basis. Surgery is delayed when possible and less invasive percutaneous options should be considered if feasible. If surgery is unavoidable, attention is paid to exercising meticulous techniques, avoiding excessive hypothermia, treating coexisting issues such as sepsis and correcting the coagulopathy with antidotes, reversal agents and blood products, with the understanding that a normal coagulation profile does not necessarily translate into hemostasis or the absence of thrombosis. Proper knowledge of the mechanism of action of the oral anticoagulants, available antidotes and their time to onset are essential in properly treating this difficult patient population.

Disseminated intravascular coagulopathy following fatal brown spider bite (necrotic arachnidism)

1972 ◽  
Vol 80 (6) ◽  
pp. 1035-1037 ◽  
Author(s):  
Hal Vorse ◽  
Paul Seccareccio ◽  
Kay Woodruff ◽  
G. Bennett Humphrey
Keyword(s):  
Disseminated Intravascular Coagulopathy ◽  
Intravascular Coagulopathy ◽  
Brown Spider ◽  
Spider Bite
Sign in / Sign up

Export Citation Format

Share Document